RHEUMATOID ARTHRITIS AND TRADITIONAL CARDIOVASCULAR RISK FACTORS: ACTUAL ASPECTS OF REAL CLINICAL PRACTICE

Cover Page

Cite item

Full Text

Abstract

Rheumatoid arthritis is a frequent and one of the most severe immuno-inflammatory diseases in humans, which determines the great medical and socio-economic importance of this pathology. One of the priority problems of modern cardiac rheumatology is an increased risk of cardiovascular complications in rheumatoid arthritis. This review discusses traditional cardiovascular risk factors for cardiovascular diseases (metabolic syndrome, obesity, dyslipidemia, hypertension, insulin resistance, diabetes mellitus, smoking and hypodynamia) and a genetic predisposition in patients with rheumatoid arthritis, as well as their specific features: "lipid paradox" and "paradox of obesity." It was noted that traditional risk factors for cardiovascular diseases are to some extent related and burdened by a systemic inflammatory process in rheumatoid arthritis, however, this relationship requires a more detailed review. The interaction of rheumatologists, cardiologists and first contact doctors (therapist and general practitioner) in studying the mechanisms of the development of atherosclerosis in patients with rheumatoid arthritis will allow in real clinical practice to develop adequate methods for the timely diagnosis and prevention of cardiovascular diseases in patients with rheumatoid arthritis.

About the authors

Dmitry I. Trukhan

Omsk State Medical University

Email: dmitry_trukhan@mail.ru
д-р мед. наук, доц., проф. каф. поликлинической терапии и внутренних болезней Omsk, Russia

Darya S. Ivanova

Omsk State Medical University

канд. мед. наук, доц. каф. поликлинической терапии и внутренних болезней Omsk, Russia

Kristina D. Belus

Omsk State Medical University

студентка 6-го курса лечебного фак-та Omsk, Russia

References

  1. Клинические рекомендации. Ревматоидный артрит. Ассоциация ревматологов России. 2018 г. http://cr.rosminzdrav.ru/#!/recomend/173 [Clinical recommendations. Rheumatoid arthritis. Association of Rheumatologists of Russia. 2018 year. http://cr.rosminzdrav.ru/#!/recomend/173 (in Russian).]
  2. Smolen JS, Aletaha D, Mclnnes IB. Rheumatoid arthritis. Lancet 2016; 388 (10055): 2023-38. doi: 10.1016/S01406736 (16)30173-8
  3. Насонов Е.Л. Российские клинические рекомендации. Ревматология М.: ГЭОТАР-Медиа, 2017. https://www.rosmedlib.ru/book/ISBN9785970442616.html [Nasonov EL. Russian clinical recommendations. Rheumatology Moscow: GEOTAR-Media, 2017. https://www.rosmedlib.ru/book/ISBN9785970442616.html (in Russian).]
  4. Галушко Е.А., Насонов Е.Л. Распространенность ревматических заболеваний в России. Альманах клин. медицины. 2018; 46 (1): 32-9. doi: 10.18786/2072-0505-2018-461-32-39 [Galushko E.A., Nasonov E.L. Prevalence of rheumatic diseases in Russia. Al'manakh klin. meditsiny. 2018; 46 (1): 32-9. doi: 10.18786/2072-0505-2018-461-32-39 (in Russian).]
  5. Naranjo A, Sokka T, Descalzo MA et al; QUEST-RA Group. Cardiovascular disease in patients with rheumatoid arthritis: results from the QUEST-RA study. Arthritis Res Ther 2008; 10 (2): R30. doi: 10.1186/ar2383
  6. Lopez-Longo FJ, Oliver-Minarro D, de la Torre I et al. Association between anti-cyclic citrullinated peptide antibodies and ischemic heart disease in patients with rheumatoid arthritis. Arthritis Rheum 2009; 61 (4): 419-24. doi: 10.1002/art.24390
  7. Berendsen MLT, van Maaren MC, Arts EEA et al. Anticyclic Citrullinated Peptide Antibodies and Rheumatoid Factor as Risk Factors for 10-year Cardiovascular Morbidity in Patients with Rheumatoid Arthritis: A Large Inception Cohort Study. J Rheumatol 2017; 44 (9): 1325-30. doi: 10.3899/jrheum.160670
  8. Mavrogeni S, Dimitroulas T, Bucciarelli-Ducci C et al. Rheumatoid arthritis: an autoimmune disease with female preponderance and cardiovascular risk equivalent to diabetes mellitus: role of cardiovascular magnetic resonance. Inflamm Allergy Drug Targets 2014; 13 (2): 81-93. doi: 10.2174/1871528113666140131151522
  9. Pujades-Rodriguez M, Duyx B, Thomas SL et al. Rheumatoid Arthritis and Incidence of Twelve Initial Presentations of Cardiovascular Disease: A Population Record-Linkage Cohort Study in England. PLoS One 2016; 11 (3): e0151245. doi: 10.1371/journal.pone.0151245. eCollection 2016.
  10. Urman A, Taklalsingh N, Sorrento C, McFarlane IM. Inflammation beyond the Joints: Rheumatoid Arthritis and Cardiovascular Disease. Scifed J Cardiol 2018; 2 (3). pii: 1000019. https: //www.ncbi.nlm.nih.gov/pmc/articles/PMC6312687/
  11. Avina-Zubieta JA, Thomas J, Sadatsafavi M et al. Risk of incident cardiovascular events in patients with rheumatoid arthritis: a meta-analysis of observational studies. Ann Rheum Dis 2012; 71 (9): 1524-9. doi: 10.1136/annrheumdis-2011-200726
  12. Попкова Т.В., Новикова Д.С., Насонов Е.Л. Сердечно-сосудистые заболевания при ревматоидном артрите: новые данные. Научно-практическая ревматология. 2016; 54 (2): 122-8. http://dx.doi.org/10.14412/1995-4484-2016-122-128 [Popkova TV., Novikova D.S., Nasonov E.L. Cardiovascular diseases in rheumatoid arthritis: Latest data. Rheumatology Science and Practice. 2016; 54 (2): 122-8. http://dx.doi.org/10.14412/1995-4484-2016-122-128 (in Russian).]
  13. Ruscitti P, Cipriani P, Masedu F et al. Increased Cardiovascular Events and Subclinical Atherosclerosis in Rheumatoid Arthritis Patients: 1 Year Prospective Single Centre Study. PLoS One 2017; 12 (1): e0170108. doi: 10.1371/journal.pone.0170108. eCollection 2017.
  14. Maradit-Kremers H, Crowson CS, Nicola PJ et al. Increased unrecognized coronary heart disease and sudden deaths in rheumatoid arthritis: a population-based cohort study. Arthritis Rheum 2005; 52 (2): 402-11. doi: 10.1002/art.20853
  15. Rawla P Cardiac and vascular complications in rheumatoid arthritis. Reumatologia 2019; 57 (1): 27-36. doi: 10.5114/reum.2019.83236
  16. Chung CP, Solus JF, Oeser A et al. A variant in the osteoprotegerin gene is associated with coronary atherosclerosis in patients with rheumatoid arthritis: results from a candidate gene study. Int J Mol Sci 2015; 16 (2): 3885-94. doi: 10.3390/ijms16023885
  17. Meyer PW, Anderson R, Ker JA, Ally MT. Rheumatoid arthritis and risk of cardiovascular disease. Cardiovasc J Afr 2018; 29 (5): 317-21. doi: 10.5830/CVJA-2018-018
  18. Jagpal A, Navarro-Millan I. Cardiovascular comorbidity in patients with rheumatoid arthritis: a narrative review of risk factors, cardiovascular risk assessment and treatment. BMC Rheumatol 2018; 2: 10. doi: 10.1186/s41927-018-0014-y. eCollection 2018.
  19. Трухан Д.И., Викторова И.А. Нефрология. Эндокринология. Гематология. СПб.: СпецЛит, 2017. https://fictionbook.ru/author/d_i_truhan/nefrologiya_yendokrinologiya_gematologiya/ [Trukhan D.I., Viktorova I.A. Nefrologij a. Jendokrinologij a. Gematologija. Saint Petersburg: SpecLit, 2017. https://fictionbook.ru/author/d_i_truhan/nefrologiya_yendokrinologiya_gematologiya/ (in Russian).]
  20. Kuriya B, Schieir O, Valois MF et al; CATCH investigators.Prevalence and Characteristics of Metabolic Syndrome Differ in Men and Women with Early Rheumatoid Arthritis. ACR Open Rheumatol 2019; 1 (9): 535-41. doi: 10.1002/acr2.11075. eCollection 2019.
  21. Kerekes G, Nurmohamed MT, Gonzalez-Gay MA et al. Rheumatoid arthritis and metabolic syndrome. Nat Rev Rheumatol 2014; 10 (11): 691-6. doi: 10.1038/nrrheum.2014.121
  22. Sule S, Fontaine K. Metabolic syndrome in adults with a history of juvenile arthritis. Open Access Rheumatol 2018; 10: 67-72. doi: 10.2147/OARRR.S157229. eCollection 2018.
  23. De Assis MR, Serafim PA. Rheumatoid arthritis and metabolic syndrome. Rev Bras Reumatol Engl Ed 2016; 56 (2): 93-4. doi: 10.1016/j.rbre.2016.02.015
  24. Pandey PK, Swami A, Biswas TK, Thakuria R. Prevalence of Metabolic Syndrome in Treatment Naive Rheumatoid Arthritis and Correlation With Disease Parameters. Arch Rheumatol 2016; 32 (1): 46-52. doi: 10.5606/ArchRheumatol.2017.5949. eCollection 2017 Mar.
  25. Hallajzadeh J, Safiri S, Mansournia MA et al. Metabolic syndrome and its components among rheumatoid arthritis patients: A comprehensive updated systematic review and meta-analysis. PLoS One 2017; 12 (3): e0170361. doi: 10.1371/journal.pone.0170361. eCollection 2017.
  26. Gomes KWP, Luz AJP, Felipe MRB et al. Prevalence of metabolic syndrome in rheumatoid arthritis patients from Northeastern Brazil: Association with disease activity. Mod Rheumatol 2018; 28 (2): 258-63. doi: 10.1080/14397595.2017.1316813
  27. Ozkul 0, Yazici A, Akturk AS et al. Are there any differences among psoriasis, psoriatic arthritis and rheumatoid arthritis in terms of metabolic syndrome and cardiovascular risk factors? Eur J Rheumatol 2018; 6 (4): 174-8. doi: 10.5152/eurjrheum.2019.19029
  28. Zaragoza-Garcia O, Navarro-Zarza JE, Maldonado-Anicacio JY et al. Hypertriglyceridaemic waist is associated with hyperuricaemia and metabolic syndrome in rheumatoid arthritis patients. Diabetes Metab Syndr 2019; 13 (1): 722-9. doi: 10.1016/j.dsx.2018.11.053
  29. Naidu G, Bhilave N, Sharma K et al. Prevalence of Metabolic Syndrome in Rheumatoid Arthritis Patients: A Case Control Study from a Tertiary Care Centre in North India. J Assoc Physicians India 2019; 67 (7): 22-4. https://www.ncbi.nlm.nih.gov/pubmed/31559763
  30. Akbal N, Aydin K, Tezcan ME. Metabolic syndrome is not uncommon in treatment-naive rheumatoid arthritis patients. Neth J Med 2019; 77 (6): 204-9. https://www.ncbi.nlm.nih.gov/pubmed/31391326
  31. Medina G, Vera-Lastra O, Peralta-Amaro AL et al. Metabolic syndrome, autoimmunity and rheumatic diseases. Pharmacol Res 2018; 133: 277-88. doi: 10.1016/j.phrs.2018.01.009
  32. Francisco V, Ruiz-Fernandez C, Pino J et al. Linking metabolic syndrome, the immune system, and arthritic diseases. Biochem Pharmacol 2019; 165: 196-206. doi: 10.1016/j.bcp.2019.03.030
  33. Batun-Garrido JAJ, Salas-Magana M, Juarez-Rojop IE et al. Relationship between leptin concentrations and disease activity in patients with rheumatoid arthritis. Med Clin (Barc) 2018; 150 (9): 3414. doi: 10.1016/j.medcli.2017.10.020
  34. Batun-Garrido JAJ, Salas-Magana M, Juarez-Rojop IE. Association between leptin and IL-6 concentrations with cardiovascular risk in patients with rheumatoid arthritis. Clin Rheumatol 2018; 37 (3): 631-7. doi: 10.1007/s10067-017-3897-x
  35. Liao KP, Solomon DH. Traditional cardiovascular risk factors, inflammation and cardiovascular risk in rheumatoid arthritis. Rheumatology (Oxford) 2013; 52 (1): 45-52. doi: 10.1093/rheumatology/kes243
  36. De Resende Guimaraes MFB, Rodrigues CEM, Gomes KWP et al. High prevalence of obesity in rheumatoid arthritis patients: association with disease activity, hypertension, dyslipidemia and diabetes, a multi-center study. Adv Rheumatol 2019; 59 (1): 44. doi: 10.1186/s42358-019-0089-1
  37. Philippou E, Nikiphorou E. Are we really what we eat? Nutrition and its role in the onset of rheumatoid arthritis. Autoimmun Rev 2018; 17 (11): 1074-7. doi: 10.1016/j.autrev.2018.05.009
  38. Kremers HM, Nicola PJ, Crowson CS et al. Prognostic importance of low body mass index in relation to cardiovascular mortality in rheumatoid arthritis. Arthritis Rheum 2004; 50 (11): 3450-7. doi: 10.1002/art.20612
  39. Armstrong DJ, McCausland EM, Quinn AD, Wright GD. Obesity and cardiovascular risk factors in rheumatoid arthritis. Rheumatology (Oxford) 2006; 45 (6): 782. doi: 10.1093/rheumatology/kel124
  40. Stavropoulos-Kalinoglou A, Metsios GS, Panoulas VF et al. Associations of obesity with modifiable risk factors for the development of cardiovascular disease in patients with rheumatoid arthritis. Ann Rheum Dis 2009; 68 (2): 242-5. doi: 10.1136/ard.2008.095596
  41. Mankad R. Atherosclerotic vascular disease in the autoimmune rheumatologic patient. Curr Athe-roscler Rep 2015; 17 (4): 497. doi: 10.1007/s11883-015-0497-6
  42. Sparks JA, Chang SC, Nguyen US et al. Weight Change During the Early Rheumatoid Arthritis Period and Risk of Subsequent Mortality in Women With Rheumatoid Arthritis and Matched Comparators. Arthritis Rheumatol 2018; 70 (1): 18-29. doi: 10.1002/art.40346
  43. Baker JF, Billig E, Michaud K et al. Weight Loss, the Obesity Paradox, and the Risk of Death in Rheumatoid Arthritis. Arthritis Rheumatol 2015; 67 (7): 1711-7. doi: 10.1002/art.39136
  44. Gonzalez A, Maradit Kremers H et al. The widening mortality gap between rheumatoid arthritis patients and the general population. Arthritis Rheum 2007; 56 (11): 3583-7. doi: 10.1002/art.22979
  45. Wolfe F, Michaud K. Effect of body mass index on mortality and clinical status in rheumatoid arthritis. Arthritis Care Res (Hoboken) 2012; 64 (10): 1471-9. doi: 10.1002/acr.21627
  46. Sattar N, McInnes IB. Rheumatoid arthritis: Debunking the obesity-mortality paradox in RA. Nat Rev Rheumatol 2015; 11 (8): 445-6. doi: 10.1038/nrrheum.2015.93
  47. Baker JF, Kerr G, Mikuls TR. Does Rheumatoid Arthritis Cause an Obesity Paradox? Comment on the Article by Sparks et al. Arthritis Rheumatol 2018; 70 (4): 627. doi: 10.1002/art.40412
  48. Roubenoff R. Rheumatoid cachexia: a complication of rheumatoid arthritis moves into the 21 stv century. Arthritis Res Ther 2009; 11 (2): 108. doi: 10.1186/ar2658
  49. Cutolo M, Nikiphorou E. Don't neglect nutrition in rheumatoid arthritis! RMD Open 2018; 4 (1): e000591. doi: 10.1136/rmdopen-2017-000591. eCollection 2018.
  50. Roubenoff R, Roubenoff RA, Ward LM et al. Rheumatoid cachexia: depletion of lean body mass in rheumatoid arthritis. J Rheumatol 1992; 19 (10): 1505-10. https://www.ncbi.nlm.nih.gov/pubmed/1464859
  51. Engvall IL, Elkan AC, Tengstrand B et al. Cachexia in rheumatoid arthritis is associated with inflammatory activity, physical disability, and low bioavailable insulin-like growth factor. Scand J Rheumatol 2008; 37 (5): 321-8. doi: 10.1080/03009740802055984
  52. Escalante A, Haas RW, del Rincon I. Paradoxical effect of body mass index on survival in rheumatoid arthritis: role of comorbidity and systemic inflammation. Arch Intern Med 2005; 165 (14): 1624-9. doi: 10.1001/archinte.165.14.1624
  53. Stavropoulos-Kalinoglou A, Metsios GS, Koutedakis Y Kitas GD. Obesity in rheumatoid arthritis. Rheumatology (Oxford) 2011; 50 (3): 450-62. doi: 10.1093/rheumatology/keq266
  54. Stavropoulos-Kalinoglou A, Metsios GS, Koutedakis Y et al. Redefining overweight and obesity in rheumatoid arthritis patients. Ann Rheum Dis 2007; 66 (10): 1316-21. doi: 10.1136/ard.2006.060319
  55. Dessein PH, Norton GR, Woodiwiss AJ et al. Independent role of conventional cardiovascular risk factors as predictors of C-reactive protein concentrations in rheumatoid arthritis. J Rheumatol 2007; 34 (4): 681-8. https://journals.co.za/content/cardio1/18B/EJC22990
  56. Трухан Д.И., Филимонов С.Н. Болезни сердечно-сосудистой системы: клиника, диагностика и лечение. СПб.: СпецЛит, 2016. https://www.libfox.ru/654075-dmitriy-truhan-klinika-diagnostika-i-lechenie-osnovnyh-revmaticheskih-bolezney.html [Trukhan D.I., Filimonov S.N. Bolezni serdechno-sosudistoj sistemy: klinika, diagnostika i lechenie. Saint Petersburg: SpecLi t, 2016. https://www.libfox.ru/654075-dmitriy-truhan-klinika-diagnostika-i-lec-henie-osnovnyh-revmaicheskih-bolezney.html (in Russian).]
  57. Panopoulos S, Tektonidou M, Drosos AA et al. Prevalence of comorbidities in systemic sclerosis versus rheumatoid arthritis: a comparative, multicenter, matched-cohort study. Arthritis Res Ther 2018; 20 (1): 267. doi: 10.1186/s13075-018-1771-0
  58. Kurmann RD, Mankad R. Atherosclerotic vascular disease in the autoimmune rheumatologic woman. Clin Cardiol 2018; 41 (2): 258-63. doi: 10.1002/clc.22916
  59. Gobbi CA, Asbert P,Alba PB et al. Lipid profile in early arthritis and its relation with inflammatory activity. Rev Fac Cien Med Univ Nac Cordoba 2017; 74 (3): 256-62. doi: 10.31053/1853.0605.v74.n3.16623
  60. Lawler PR, Akinkuolie AO, Ridker PM et al. Discordance between Circulating Atherogenic Cholesterol Mass and Lipoprotein Particle Concentration in Relation to Future Coronary Events in Women. Clin Chem 2017; 63 (4): 870-9. doi: 10.1373/clinchem.2016.264515
  61. Mackey RH, Kuller LH, Moreland LW. Update on Cardiovascular Disease Risk in Patients with Rheumatic Diseases. Rheum Dis Clin North Am 2018; 44 (3): 475-87. doi: 10.1016/j.rdc.2018.03.006
  62. Hollan I, Ronda N, Dessein P et al. Lipid management in rheumatoid arthritis: a position paper by the Cardiovascular Pharmacotherapy Working Group of European Society of Cardiology. Eur Heart J Cardiovasc Pharmacother 2019. pii: pvz033. doi: 10.1093/ehjcvp/pvz033
  63. Sun DM, Ding Y, Zhnag Y, Xia K. Serum lipid profile in children with different subtypes of juvenile idiopathic arthritis. Zhongguo Dang Dai Er Ke Za Zhi 2019; 21 (6): 547-51. https://www.ncbi.nlm.nih.gov/pubmed/31208507
  64. McGrath CM, Young SP. Lipid and Metabolic Changes in Rheumatoid Arthritis. Curr Rheumatol Rep 2015; 17 (9): 57. doi: 10.1007/s11926-015-0534-z
  65. Liao KP, Playford MP, Michelle F et al. The association between reduction in inflammation and changes in lipoprotein levels and HDL cholesterol efflux capacity in rheumatoid arthritis. J Am Heart Assoc 2015; (2). pii: e001588. doi: 10.1161/JAHA.114.001588
  66. Berrougui H, Momo CN, Khalil A. Health benefits of high-density lipoproteins in preventing cardiovascular diseases. J Clin Lipidol 2012; 6 (6): 524-33. doi: 10.1016/j.jacl.2012.04.004
  67. Raterman HG, Levels H, Voskuyl AE et al. HDL protein composition alters from proatherogenic into less atherogenic and proinflammatory in rheumatoid arthritis patients responding to rituximab. Ann Rheum Dis 2013; 72 (4): 560-5. doi: 10.1136/annrheumdis-2011-201228
  68. Jamnitski A, Levels JH, van den Oever IA, Nurmohamed MT. High-density lipoprotein profiling changes in patients with rheumatoid arthritis treated with tumor necrosis factor inhibitors: a cohort study. J Rheumatol 2013; 40 (6): 825-30. doi: 10.3899/jrheum.121358
  69. Agca R, Heslinga SC, van Halm VP, Nurmohamed MT. Atherosclerotic cardiovascular disease in patients with chronic inflammatory joint disorders. Heart 2016; 102 (10): 790-5. doi: 10.1136/heartjnl-2015-307838
  70. Crowson CS, Rollefstad S, Ikdahl E et al; A Trans-Atlantic Cardiovascular Consortium for Rheumatoid Arthritis (ATACC-RA). Impact of risk factors associated with cardiovascular outcomes in patients with rheumatoid arthritis. Ann Rheum Dis 2018; 77 (1): 48-54. doi: 10.1136/annrheumdis-2017-211735
  71. Paraskevas KI. Statin treatment for rheumatoid arthritis: a promising novel indication. Clin Rheumatol 2008; 27 (3): 281-7. doi: 10.1007/s10067-007-0806-8
  72. Gobbi CA, Asbert P,Alba PB et al. Lipid profile in early arthritis and its relation with inflammatory activity. Rev Fac Cien Med Univ Nac Cordoba 2017; 74 (3): 256-62. doi: 10.31053/1853.0605.v74.n3.16623
  73. Castro LL, Lanna CCD, Rocha MP et al. Recognition and control of hypertension, diabetes, and dyslipidemia in patients with rheumatoid arthritis. Rheumatol Int 2018; 38 (8): 1437-42. doi: 10.1007/s00296-018-4084-3
  74. Panoulas VF, Douglas KM, Milionis HJ et al. Prevalence and associations of hypertension and its control in patients with rheumatoid arthritis. Rheumatology (Oxford) 2007; 46 (9): 1477-82. doi: 10.1093/rheumatology/kem169
  75. Protogerou AD, Panagiotakos DB, Zampeli E et al. Arterial hypertension assessed "out-of-office" in a contemporary cohort of rheumatoid arthritis patients free of cardiovascular disease is characterized by high prevalence, low awareness, poor control and increased vascular damage-associated "white coat" phenomenon. Arthritis Res Ther 2013; 15 (5): R142. doi: 10.1186/ar4324
  76. Шилкина Н.П., Юнонин И.Е., Бутусова С.В. и др. Повреждение эндотелия и суточный профиль артериального давления при ревматоидном артрите. Терапевтический архив. 2019; 91 (5): 89-95. doi: 10.26442/00403660.2019.05.000052 [Shilkina N.P., Yunonin I.E., Butusova S.V. et al. Endothelial damage and circadian blood pressure profile in rheumatoid arthritis. Therapeutic Archive. 2019; 91 (5): 86-95. doi: 10.26442/00403660.2019.05.000052 (in Russian).]
  77. De Groot L, Jager NA. Does reduction of disease activity improve early markers of cardiovascular disease in newly diagnosed rheumatoid arthritis patients? Rheumatology 2015; 54: 1257-61. doi: 10.1093/rheumatology/keu459
  78. Cohen Tervaert JW. Hypertension: an autoimmune disease? Hypertens Res 2011; 34 (4): 443-4. doi: 10.1038/hr.2011.15
  79. Новикова Д.С., Попкова Т.В., Насонов Е.Л. Артериальная гипертензия при ревматоидном артрите. Научно-практическая ревматология. 2011; 49 (3): 52-68. https://doi.org/10.14412/1995-4484-2011-574 [Novikova D.S., Popkova TV., Nasonov E.L. Arterial hypertension in rheumatoid arthritis. Rheumatology Science and Practice. 2011; 49 (3): 52-68. https://doi.org/10.14412/1995-4484-2011-574 (in Russian).]
  80. Chung CP, Oeser A, Solus JF et al. Inflammation-associated insulin resistance: differential effects in rheumatoid arthritis and systemic lupus erythematosus define potential mechanisms. Arthritis Rheum 2008; 58 (7): 2105-12. doi: 10.1002/art.23600
  81. Ursini F, Russo E, D’Angelo S et al. Prevalence of undiagnosed diabetes in rheumatoid arthritis: an OGTT study. Medicine (Baltimore) 2016; 95 (7): e2552. doi: 10.1097/MD.0000000000002552
  82. Ruscitti P, Ursini F, Cipriani P et al. Prevalence of type 2 diabetes and impaired fasting glucose in patients affected by rheumatoid arthritis: results from a cross-sectional study. Medicine (Baltimore) 2017; 96 (34): e7896. doi: 10.1097/MD.0000000000007896
  83. Pi H, Zhou H, Jin H et al. Abnormal Glucose Metabolism in Rheumatoid Arthritis. Biomed Res Int 2017; 2017: 9670434. doi: 10.1155/2017/9670434
  84. Contreras-Haro B, Hernandez-Gonzalez SO, Gonzalez-Lopez L et al. Fasting triglycerides and glucose index: a useful screening test for assessing insulin resistance in patients diagnosed with rheumatoid arthritis and systemic lupus erythematosus. Diabetol Metab Syndr 2019; 11: 95. doi: 10.1186/s13098-019-0495-x. eCollection 2019.
  85. Hoes JN, van der Goes MC, van Raalte DH et al. Glucose tolerance, insulin sensitivity and b-cell function in patients with rheumatoid arthritis treated with or without low-to-medium dose glucocorticoids. Ann Rheum Dis 2011; 70 (11): 1887-94. doi: 10.1136/ard.2011.151464
  86. Simard JF, Mittleman MA. Prevalent rheumatoid arthritis and diabetes among NHANES III participants aged 60 and older. J Rheumatol 2007; 34 (3): 469-73. https://www.ncbi.nlm.nih.gov/pubmed/17183622
  87. Nicolau J, Lequerre T, Bacquet H, Vittecoq O. Rheumatoid arthritis, insulin resistance, and diabetes. Joint Bone Spine 2017; 84 (4): 411-6. doi: 10.1016/j.jbspin.2016.09.001
  88. Solomon DH, Karlson EW, Rimm EB et al. Cardiovascular morbidity and mortality in women diagnosed with rheumatoid arthritis. Circulation 2003; 107 (9): 1303-7. doi: 10.1161/01.cir.0000054612.26458.b2
  89. Solomon DH, Love TJ, Canning C, Schneeweiss S. Risk of diabetes among patients with rheumatoid arthritis, psoriatic arthritis and psoriasis. Ann Rheum Dis 2010; 69 (12): 2114-7. doi: 10.1136/ard.2009.125476
  90. Gallagher L, Cregan S, Biniecka M et al. Insulin Resistant Pathways are associated with Disease Activity in Rheumatoid Arthritis and are Subject to Disease Modification through Metabolic Reprogramming; A Potential Novel Therapeutic Approach. Arthritis Rheumatol 2019. doi: 10.1002/art.41190
  91. Попкова Т.В., Новикова Д.С., Насонов Е.Л. Кардиоваскулярные факторы риска при ревматических заболеваниях: связь с воспалением. Consilium Medicum. 2010; 12 (2): 112-8. https://con-med.ru/magazines/consilium_medicum/consilium_medicum-02-2010/kardiovaskulyarnye_ faktory_riska_pri_revmaticheskikh_zabolevaniyakh_svyaz_s_vospaleniem_
  92. Giacomelli R, Ruscitti P, Alvaro S et al. IL-1b at the crossroad between rheumatoid arthritis and type 2 diabetes: may we kill two birds with one stone? Expert Rev Clin Immunol 2016; 12 (8): 849-55. doi: 10.1586/1744666X.2016.1168293
  93. Ruscitti P, Ursini F, Cipriani P et al. IL-1 inhibition improves insulin resistance and adipokines in rheumatoid arthritis patients with comorbid type 2 diabetes: An observational study. Medicine (Baltimore) 2019; 98 (7): e14587. doi: 10.1097/MD.0000000000014587
  94. Corrado A, Colia R, Rotondo C et al. Changes in serum adipokines profile and insulin resistance in patients with rheumatoid arthritis treated with anti-TNF-a. Curr Med Res Opin 2019; 35 (12): 2197205. doi: 10.1080/03007995.2019.1654988
  95. Castaneda S, Remuzgo-Martinez S, Lopez-Mejias R et al. Rapid beneficial effect of the IL-6 receptor blockade on insulin resistance and insulin sensitivity in non-diabetic patients with rheumatoid arthritis. Clin Exp Rheumatol 2019; 37 (3): 465-73. https://www.ncbi.nlm.nih.gov/pubmed/30418124
  96. Costenbader KH, Feskanich D, Mandl LA, Karlson EW. Smoking intensity, duration, and cessation, and the risk of rheumatoid arthritis in women. Am J Med 2006; 119 (6): 503.e1-9. doi: 10.1016/amj-med.2005.09.053
  97. Crowson CS, Rollefstad S, Kitas GD et al; A Trans-Atlantic Cardiovascular Risk Consortium for Rheumatoid Arthritis (ATACC-RA). Challenges of developing a cardiovascular risk calculator for patients with rheumatoid arthritis. PLoS One 2017; 12 (3): e0174656. doi: 10.1371/journal.pone.0174656. eCollection 2017.
  98. Legge A, Hanly JG. Managing premature atherosclerosis in patients with chronic inflammatory diseases. CMAJ 2018; 190 (14): 430-9. doi: 10.1503/cmaj.170776
  99. Chang K, Yang SM, Kim SH et al. Smoking and rheumatoid arthritis. Int J Mol Sci 2014; 15: 2227995. Int J Mol Sci 2014; 15 (12): 22279-95. doi: 10.3390/ijms151222279
  100. Sparks JA, Karlson EW.The Roles of Cigarette Smoking and the Lung in the Transitions Between Phases of Preclinical Rheumatoid Arthritis. Curr Rheumatol Rep 2016; 18 (3): 15. doi: 10.1007/s11926-016-0563-2
  101. Sugiyama D, Nishimura K, Tamaki K et al. Impact of smoking as a risk factor for developing rheumatoid arthritis: a meta-analysis of observational studies. Ann Rheum Dis 2010; 69 (1): 70-81. doi: 10.1136/ard.2008.096487
  102. De Hair MJ, Landewe RB, van de Sande MG et al. Smoking and overweight determine the likelihood of developing rheumatoid arthritis. Ann Rheum Dis 2013; 72 (10): 1654-8. doi: 10.1136/annrheum-dis-2012-202254
  103. Rojas-Serrano J, Perez LL, Garcia CG et al. Current smoking status is associated to a non-ACR 50 response in early rheumatoid arthritis. A cohort study. Clin Rheumatol 2011; 30 (12): 1589-93. doi: 10.1007/s10067-011-1775-5
  104. Ishikawa Y Ikari K, Hashimoto M et al. Shared epitope defines distinct associations of cigarette smoking with levels of anticitrullinated protein antibody and rheumatoid factor. Ann Rheum Dis 2019; 78 (11): 1480-7. doi: 10.1136/annrheumdis-2019-215463
  105. Van Delft MAM, Huizinga TWJ. An overview of autoantibodies in rheumatoid arthritis. J Autoimmun 2020; p. 102392. doi: 10.1016/j.jaut.2019.102392
  106. Chung CP, Avalos I, Raggi P, Stein CM. Atherosclerosis and inflammation: insights from rheumatoid arthritis. Clin Rheumatol 2007; 26 (8): 1228-33. doi: 10.1007/s10067-007-0548-7
  107. Van Halm VP, van Denderen JC, Peters MJ et al. Increased disease activity is associated with a deteriorated lipid profile in patients with ankylosing spondylitis. Ann Rheum Dis 2006; 65 (11): 1473-7. doi: 10.1136/ard.2005.050443
  108. Veldhuijzen van Zanten JJ, Rouse PC, Hale ED et al. Perceived Barriers, Facilitators and Benefits for Regular Physical Activity and Exercise in Patients with Rheumatoid Arthritis: A Review of the Literature. Sports Med 2015; 45 (10): 1401-12. doi: 10.1007/s40279-015-0363-2
  109. Panoulas VF, Metsios GS, Pace AV et al. Hypertension in rheumatoid arthritis. Rheumatology (Oxford) 2008; 47 (9): 1286-98. doi: 10.1093/rheumatology/ken159
  110. Hernandez-Hernandez V, Ferraz-Amaro I, Diaz-Gonzalez F Influence of disease activity on the physical activity of rheumatoid arthritis patients. Rheumatology (Oxford) 2014; 53 (4): 722-31. doi: 10.1093/rheumatology/ket422
  111. O'Dwyer T, O'Shea F, Wilson F Physical activity in spondyloarthritis: a systematic review. Rheumatol Int 2015; 35 (3): 393-404. doi: 10.1007/s00296-014-3141-9
  112. Boo S, Oh H, Froelicher ES, Suh CH. Knowledge and perception of cardiovascular disease risk among patients with rheumatoid arthritis. PLoS One 2017; 12 (4): e0176291. DOI: 10.1371/j ournal.pone.0176291. eCollection 2017.
  113. Stavropoulos-Kalinoglou A, Metsios GS, Veldhuijzen van Zanten JJ et al. Individualised aerobic and resistance exercise training improves cardiorespiratory fitness and reduces cardiovascular risk in patients with rheumatoid arthritis. Ann Rheum Dis 2013; 72 (11): 1819-25. doi: 10.1136/annrheumdis-2012-202075
  114. Andrades C, Fuego C, Manrique-Arija S, Fernandez-Nebro A. Management of cardiovascular risk in systemic lupus erythematosus: a systematic review. Lupus 2017; 26 (13): 1407-19. doi: 10.1177/0961203317704710
  115. Gonzalez A, Maradit Kremers H, Crowson CS et al. Do cardiovascular risk factors confer the same risk for cardiovascular outcomes in rheumatoid arthritis patients as in non-rheumatoid arthritis patients? Ann Rheum Dis 2008; 67 (1): 64-9. doi: 10.1136/ard.2006.059980
  116. Lopez-Mejias R, Corrales A, Vicente E et al. Influence of coronary artery disease and subclinical atherosclerosis related polymorphisms on the risk of atherosclerosis in rheumatoid arthritis. Sci Rep 2017; 7: 40303. doi: 10.1038/srep40303
  117. Gonzalez-Gay MA, Garcia-Porrua C, Hajeer AH. Influence of human leukocyte antigen-DRB1 on the susceptibility and severity of rheumatoid arthritis. Semin Arthritis Rheum 2002; 31 (6): 355-60. doi: 10.1053/sarh.2002.32552
  118. Gonzalez-Juanatey C, Testa A, Garcia-Castelo A et al. HLA-DRB1 status affects endothelial function in treated patients with rheumatoid arthritis. Am J Med 2003; 114 (8): 647-52. doi: 10.1016/s0002-9343 (03)00133-5
  119. Gonzalez-Gay MA, Gonzalez-Juanatey C, Ollier WE. Endothelial dysfunction in rheumatoid arthritis: influence of HLA-DRB1 alleles. Autoimmun Rev 2004; 3 (4): 301-4. DOI: 10.1016tj.autrev.2003.10.006
  120. Gonzalez-Gay MA, Gonzalez-Juanatey C, Lopez-Diaz MJ et al. HLA-DRB1 and persistent chronic inflammation contribute to cardiovascular events and cardiovascular mortality in patients with rheumatoid arthritis. Arthritis Rheum 2007; 57 (1): 125-32. doi: 10.1002/art.22482
  121. Ollier W, Venables PJ, Mumford PA et al. HLA antigen associations with extra-articular rheumatoid arthritis. Tissue Antigens 1984; 24 (5): 279-91. doi: 10.1111/j.1399-0039.1984.tb02139.x
  122. Salvarani C, Macchioni P, Mantovani W et al. Extraarticular manifestations of rheumatoid arthritis and HLA antigens in northern Italy. J Rheumatol 1992; 19 (2): 242-6. https://www.ncbi.nlm.nih.gov/pub-med/1629822
  123. Weyand CM, Hicok KC, Conn DL, Goronzy JJ. The influence of HLA-DRB1 genes on disease severity in rheumatoid arthritis. Ann Intern Med 1992; 117 (10): 801-6. doi: 10.7326/0003-4819-117-10-801
  124. Perdriger A, Chales G, Semana G et al. Role of HLA-DR-DR and DR-DQ associations in the expression of extraarticular manifestations and rheumatoid factor in rheumatoid arthritis. J Rheumatol 1997; 24 (7): 1272-6. https://www.ncbi.nlm.nih.gov/pubmed/9228123
  125. Panoulas VF, Stavropoulos-Kalinoglou A, Metsios GS et al. Association of interleukin-6 (IL-6)-174G/C gene polymorphism with cardiovascular disease in patients with rheumatoid arthritis: the role of obesity and smoking. Atherosclerosis 2009; 204 (1): 178-83. DOI: 10.1016j.atherosclerosis.2008.08.036
  126. Lopez-Mejias R, Castaneda S, Gonzalez-Juanatey C et al. Cardiovascular risk assessment in patients with rheumatoid arthritis: The relevance of clinical, genetic and serological markers. Autoimmun Rev 2016; 15 (11): 1013-30. doi: 10.1016/j.autrev.2016.07.026
  127. Ghosh-Swaby OR, Kuriya B. Awareness and perceived risk of cardiovascular disease among individuals living with rheumatoid arthritis is low: results of a systematic literature review. Arthritis Res Ther 2019; 21 (1): 33. doi: 10.1186/s13075-019-1817-y
  128. Дутова А.Ю., Кабирова А.К., Аршин Е.В., Туев А.В. Вклад традиционных факторов риска (ТФР) в уровень сердечно-сосудистой смертности (ССС) у больных ревматоидным артритом. В сб.: Научная сессия Пермского государственного медицинского университета им. акад. Е.А. Вагнера. 2015; с. 16-8. https://elibrary.ru/item.asp?id=24821767
  129. Agca R, Heslinga SC, Rollefstad S et al. EULAR recommendations for cardiovascular disease risk management in patients with rheumatoid arthritis and other forms of inflammatory joint disorders: 2015/2016 update. Ann Rheum Dis 2017; 76 (1): 17-28. doi: 10.1136/annrheumdis-2016-209775
  130. Zegkos T, Kitas G, Dimitroulas T Cardiovascular risk in rheumatoid arthritis: assessment, management and next steps. Ther Adv Musculoskelet Dis 2016; 8 (3): 86-101. doi: 10.1177/1759720X16643340
  131. Ladak K, Hashim J, Clifford-Rashotte M et al. Cardiovascular risk management in rheumatoid arthritis: A large gap to close. Musculoskeletal Care 2018; 16 (1): 152-7. doi: 10.1002/msc.1196
  132. Hollan I, Dessein PH, Ronda N et al. Prevention of cardiovascular disease in rheumatoid arthritis. Autoimmun Rev 2015; 14 (10): 952-69. doi: 10.1016/j.autrev.2015.06.004
  133. Day AL, Singh JA. Cardiovascular Disease Risk in Older Adults and Elderly Patients with Rheumatoid Arthritis: What Role Can Disease-Modifying Antirheumatic Drugs Play in Cardiovascular Risk Reduction? Drugs Aging 2019; 36 (6): 493-510. doi: 10.1007/s40266-019-00653-0

Copyright (c) 2020 Consilium Medicum

Creative Commons License
This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.

This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies